Celldex Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 26, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | ||
|---|---|---|
| | CELLDEX THERAPEUTICS, INC. | |
| | | |
| | By: | /s/ ANTHONY S. MARUCCI |
| DateFebruary 26, 2024 | | Anthony S. MarucciPresident and Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date | ||
|---|---|---|---|---|
| | | | | |
| /s/ ANTHONY S. MARUCCI | | President, Chief Executive Officer, and Director | | February 26, 2024 |
| Anthony S. Marucci | | (Principal Executive Officer) | | |
| | | | | |
| /s/ SAM MARTIN | | Senior Vice President, | | February 26, 2024 |
| Sam Martin | | Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) | | |
| | | | | |
| /s/ KAREN L. SHOOS | | Director, Chair of the Board of Directors | | February 26, 2024 |
| Karen L. Shoos | | | | |
| | | | | |
| /s/ KEITH L. BROWNLIE | | Director | | February 26, 2024 |
| Keith L. Brownlie | | | | |
| | | | | |
| /s/ CHERYL L. COHEN | | Director | | February 26, 2024 |
| Cheryl L. Cohen | | | | |
| | | | | |
| /s/ HERBERT J. CONRAD | | Director | | February 26, 2024 |
| Herbert J. Conrad | | | | |
| | | | | |
| /s/ RITA I. JAIN, M.D, | | Director | | February 26, 2024 |
| Rita I. Jain, M.D. | | | | |
| | | | | |
| /s/ JAMES J. MARINO | | Director | | February 26, 2024 |
| James J. Marino | | | | |
| | | | | |
| /s/ GARRY A. NEIL, M.D. | | Director | | February 26, 2024 |
| Garry A. Neil, M.D. | | | | |
| | | | | |
| /s/ HARRY H. PENNER, JR. | | Director | | February 26, 2024 |
| Harry H. Penner, Jr. | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.